chartexchange

Atrium Therapeutics Reports Third Quarter 2026 Financial Results

PR Newswire | Nov 12, 2026 4:10 PM EST

-- First patient dosed with ATR 1072 in the Corventis™ Phase 1/2 clinical trial in PRKAG2 syndrome -- -- Nonclinical data showed ATR 1072 reversed cardiac glycogen accumulation and improved features of PRKAG2 syndrome -- -- Pro-forma cash balance at the end of September 2026 was $293.6...

Read original article